<DOC>
	<DOCNO>NCT00771875</DOCNO>
	<brief_summary>This study conduct determine safe effective use immune cell ( b cell ) deplete therapy and/or Thymoglobulin patient kidney transplant experience certain type rejection .</brief_summary>
	<brief_title>Randomized Trial Mixed Acute Rejection</brief_title>
	<detailed_description>The purpose study determine safety efficacy treatment mixed ( cellular antibody ) mediate acute rejection addition B-cell depleting therapy Thymoglobulin kidney simultaneous kidney pancreas allograft recipient .</detailed_description>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<mesh_term>Histamine Antagonists</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Inclusion Criteria Each subject must meet follow inclusion criterion enrol study : Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Female subject either postmenopausal surgically sterilize willing use two acceptable method birth control ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . Subject 18 65 year age , inclusive . Subject transplant dysfunction indicate increase creatinine 0.3 mg/dL 15 % ( lipase &gt; 3 X ULN kidney/pancreas recipient ) baseline necessitate allograft biopsy ass allograft rejection . Presence light microscopic histologic change consistent acute cellular rejection Banff 97 ( 2005 update ) grade IA great least one following : Donorspecific antibody ( DSA ) positive via Luminex Presence C4d peritubular capillary glomeruli Subject must know contraindication treatment bortezomib , boron mannitol , thymoglobulin , rituximab . Recipients kidney simultaneous kidney pancreas organ transplant . Exclusion Criteria Subjects meeting follow exclusion criterion enrol study . Subject platelet count &lt; 100,000/mm3 within 7 day enrollment . Subject absolute neutrophil count &lt; 1,000/mm3 within 7 day enrollment . Subject Grade 2 peripheral neuropathy within 14 day enrollment . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( see section 8.4 ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , ECG abnormality Screening document investigator medically relevant . Subject receive investigational drug 14 day enrollment Serious medical ( renal disease ) psychiatric illness likely interfere participation clinical study . Subjects previously receive organ transplant kidney simultaneous kidney pancreas . Subjects recipients ABO incompatible transplant , cytotoxicity ( CDC ) crossmatch positive transplant Recipients simultaneous kidney pancreas transplant pancreas rejection . Subjects unable tolerate dose mycophenolate mofetil 13g/day ( equivalent mycophenolic acid dose ) . Subjects antiHIVpositive , HBsAgpositive . AntiHepatitis C Virus ( HCV ) positive patient exclude , except patient negative pathologic complete remissionresult . Recipients kidney donor test positive HIV , HBsAg antiHCV History malignancy within past 5 year consider cure , exception localize basal cell carcinoma skin ( excise â‰¥ 2 year prior randomization ) Subjects current recent severe systemic infection within 2 week prior randomization . Receipt live vaccine within 4 week prior study entry Evidence severe liver disease abnormal liver profile ( aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) total bilirubin &gt; 3 time upper limit normal ( ULN ) ) screen . Pregnant nursing ( lactate ) woman . EBV seromismatch ( EBV + donor organ transplant EBV recipient ) CMV seromismatch ( CMV + donor organ transplant CMV recipient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>